Austin, TX CME Conference

Conference Agenda

7:30 – 8:00 am
Registration & Continental Breakfast

8:15 – 8:30 am
Program Overview & Introduction
Steven V. Edelman, MD

8:30 – 9:10 am
Promoting Behavior Change in Diabetes
William Polonsky, PhD, CDE

9:10 – 10:10 am
Knowledge Gives You the Power to Take Control
Steven V. Edelman, MD

10:10 – 10:20 am
Break with Refreshments

10:20 – 11:35 am
Managing the Maze of Oral Agents for Type 2: How They Work and Where They Fit in Clinical Practice 

Robert Henry, MD

11:35 – 12:50 pm
Injectable Agents and Their Clinical Applications for the Treatment of Type 2 Diabetes: Insulin, GLP-1 Agonists and Amylin Analogs

Tom Blevins, MD

12:50 – 2:00 pm
Lunch & Visit Health Fair

2:00 – 3:15pm

The Standards of Care for Type 1: Pumps, Multiple Daily Injection Regimens, Amylin Analogs and Continuous Glucose Monitoring

Steven Edelman, MD

3:15 – 3:30 pm
Break

3:30 – 4:30 pm
The Good, The Bad and The Ugly: Developing Better Communication With Healthcare Providers and People With Diabetes
Steven V. Edelman, MD & William Polonsky, PhD, CDE

4:30 – 5:00 pm
Making the Connection
William Polonsky, PhD, CDE

The closing session will discuss participant observations and insights gained regarding the important and difficult issues that people with diabetes face on an everyday basis.

5:00 pm
Adjourn

Course Description

The TCOYD Continuing Medical Education Program offers a unique opportunity to bridge patient and professional education, demonstrating the link between clinical lessons in the classroom to the real life patient experience. The ultimate goal of this activity is to educate caregivers about the most effective cutting edge strategies to help patients with diabetes reach their treatment goals and avoid the associated acute and chronic complications. This program also aims to achieve caregiver appreciation of the many previously unrealized concerns that affect patient adherence or non-adherence with a prescribed medical regimen.

In addition, this course is being held in tandem with a separate, yet similar, large-scale patient education conference and will give providers the opportunity to observe and interact with people who have diabetes and are engaged in their own intensive educational environment. Making that connection with patients, providers will acquire new skills and insight into what empowers patients with diabetes to develop healthy self-management of their condition.

This activity will focus on three distinct areas of diabetes management, and integrate case presentations into the lectures to facilitate more active audience participation. The four areas are:

• Promoting behavioral change in diabetes
• Oral agents for use in patients with type 2 diabetes
• Injectable therapies for use in patients with type 2 diabetes
• Intensive management strategies for patients with type 1 diabetes

Participants will be encouraged to consider the various therapeutic options they learn throughout the day, as well as any barriers to good control that a particular case may present. The goal is to encourage providers to consider these cases as whole individuals, taking into account their lifestyle, beliefs, background and environment when deciding upon treatment options.

Target Audience

This course is designed for diabetes healthcare providers including: endocrinologists, primary care physicians, nurse practitioners, physician assistants, certified diabetes educators, and other medical professionals wanting to expand their knowledge of diabetes management.

At the conclusion of this program, participants should be able to:

1. Discuss with colleagues the different pathophysiologic defects associated with type 2 diabetes and how each pharmacologic agent addresses these specific abnormalities.
2. Assess the recent clinical trial data and express the concepts and practical issues of combination therapy with the currently available oral agents including metformin, TZDs, SFUs, bile acid sequestrants, DPP4 inhibitors and bromocriptine agonists.
3. Design rational and individualized treatment plans using the various medications alone or in combination, including the optimal time for introducing each therapy.
4. Describe the pros and cons of the various insulin strategies including combination therapy, the split mixed, premixed, basal-bolus and pump regimens.
5. Discuss with colleagues patient directed insulin titration strategies used in clinical practice for combination therapy and the basal bolus approach.
6. Review and describe the pathophysiology of type 2 diabetes as it relates to the role of GLP-1 and give a clinically relevant explanation of the incretin mimetic story.
7. Interpret the most up to date clinical information on GLP-1 agonists and summarize the prescribing guidelines and safety issues.
8. Illustrate the physiologic secretion of insulin, glucagon and amylin in the normal and diabetic state and propose a physiologic MDI (multiple daily injection) regimen.
9. Identify appropriate candidates for pump therapy. Design an easy-to-implement treatment plan for initiation of pump therapy and subsequent adjustments based on home glucose and/or continuous glucose monitoring numbers.
10. Discuss with colleagues scenarios illustrating the information continuous glucose monitoring technology provides, and effective therapeutic adjustments based on continuous glucose monitoring data.
11. Assess and evaluate the physical and emotional barriers that prevent patients with diabetes from adherence to their therapeutic regimen(s) and achieving metabolic control.
12. Employ innovative and dynamic strategies for communication with patients to strengthen provider patient

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, San Diego School of Medicine and Taking Control Of Your Diabetes. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

AMA: The University of California, San Diego School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

BRN: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credits™ (report up to 7.25 hours of credit and list "CME Category 1" as the provider number).

Certified Diabetes Educators: To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE list of Approved Providers (www.ncbde.org). NCBDE does not approve continuing education. The University of California, San Diego School of Medicine is accredited by the ACCME, which is on the NCBDE list of Approved Providers.

Commercial Support

This activity is supported by:
Amylin Pharmaceuticals, Inc.; Lilly USA, LLC; Bayer Healthcare Diabetes Care; BD; Merck Sharp & Dohmen Corp.; Novo Nordisk Inc.; Sanofi-Aventis U.S. Inc.; Santarus 

Statement of Need

The content of this educational activity was determined by rigorous assessment of educational need and includes expert faculty assessment, literature review, medical practice, and new medical knowledge.

Disclosure

This activity has been planned and implemented in accordance with the ACCME Essential Areas and Elements and ACCME Policies to ensure balance, independence, objectivity, and scientific rigor.  All individuals responsible for content, regardless of role(s), are required to document financial relationships or the absence of relationships with commercial interests, and all potential conflicts of interest must be resolved prior to the activity.  Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience.

Cultural and Linguistic Competency

This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enable health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and linguistic competency was incorporated into the planning of this activity.